Ge Long Hui·2025-10-21 09:48Core Insights - China National Pharmaceutical Group (国药控股) reported a decline in revenue and net profit for the first nine months of 2025, indicating challenges in the pharmaceutical sector [1] Financial Performance - For the period of January to September 2025, China National Pharmaceutical Group's subsidiary, China National Pharmaceutical (国药一致), achieved a revenue of 55.124 billion yuan, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders of China National Pharmaceutical was 0.957 billion yuan, reflecting a year-on-year decline of 10.18% [1] - Basic earnings per share decreased by 9.95%, and the weighted average return on net assets fell by 0.70 percentage points year-on-year [1] Quarterly Results - In the third quarter of 2025, China National Pharmaceutical reported a revenue of 18.328 billion yuan, down 1.89% compared to the same period last year [1] - The net profit attributable to shareholders for the third quarter was 0.291 billion yuan, showing a year-on-year decline of 9.58% [1]